Sustained plasma hepcidin suppression and iron elevation by Anticalin-derived hepcidin antagonist in cynomolgus monkey
Published 2018 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Sustained plasma hepcidin suppression and iron elevation by Anticalin-derived hepcidin antagonist in cynomolgus monkey
Authors
Keywords
-
Journal
BRITISH JOURNAL OF PHARMACOLOGY
Volume 175, Issue 7, Pages 1054-1065
Publisher
Wiley
Online
2018-01-13
DOI
10.1111/bph.14143
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Targeting iron metabolism in drug discovery and delivery
- (2017) Bart J. Crielaard et al. NATURE REVIEWS DRUG DISCOVERY
- Pharmacodynamic Model of Hepcidin Regulation of Iron Homeostasis in Cynomolgus Monkeys
- (2016) Wojciech Krzyzanski et al. AAPS Journal
- Roxadustat (FG-4592) Versus Epoetin Alfa for Anemia in Patients Receiving Maintenance Hemodialysis: A Phase 2, Randomized, 6- to 19-Week, Open-Label, Active-Comparator, Dose-Ranging, Safety and Exploratory Efficacy Study
- (2016) Robert Provenzano et al. AMERICAN JOURNAL OF KIDNEY DISEASES
- Safety, pharmacokinetics and pharmacodynamics of the anti-hepcidin Spiegelmer lexaptepid pegol in healthy subjects
- (2016) M Boyce et al. BRITISH JOURNAL OF PHARMACOLOGY
- Vadadustat, a novel oral HIF stabilizer, provides effective anemia treatment in nondialysis-dependent chronic kidney disease
- (2016) Pablo E. Pergola et al. KIDNEY INTERNATIONAL
- Iron management in chronic kidney disease: conclusions from a “Kidney Disease: Improving Global Outcomes” (KDIGO) Controversies Conference
- (2016) Iain C. Macdougall et al. KIDNEY INTERNATIONAL
- Anti-repulsive Guidance Molecule C (RGMc) Antibodies Increases Serum Iron in Rats and Cynomolgus Monkeys by Hepcidin Downregulation
- (2015) Preethne Böser et al. AAPS Journal
- Functional characterization of a VEGF-A-targeting Anticalin, prototype of a novel therapeutic human protein class
- (2015) Hendrik Gille et al. ANGIOGENESIS
- Experimental design and analysis and their reporting: new guidance for publication in BJP
- (2015) Michael J Curtis et al. BRITISH JOURNAL OF PHARMACOLOGY
- Implementing guidelines on reporting research using animals (ARRIVE etc.): new requirements for publication in BJP
- (2015) John C McGrath et al. BRITISH JOURNAL OF PHARMACOLOGY
- The Labile Side of Iron Supplementation in CKD
- (2015) I. Slotki et al. JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY
- Randomized placebo-controlled dose-ranging and pharmacodynamics study of roxadustat (FG-4592) to treat anemia in nondialysis-dependent chronic kidney disease (NDD-CKD) patients
- (2015) Anatole Besarab et al. NEPHROLOGY DIALYSIS TRANSPLANTATION
- Effect of the antihepcidin Spiegelmer lexaptepid on inflammation-induced decrease in serum iron in humans
- (2014) L. T. van Eijk et al. BLOOD
- Considerations and Challenges in Defining Optimal Iron Utilization in Hemodialysis
- (2014) D. M. Charytan et al. JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY
- Testosterone administration inhibits hepcidin transcription and is associated with increased iron incorporation into red blood cells
- (2013) Wen Guo et al. AGING CELL
- A fully human anti-hepcidin antibody modulates iron metabolism in both mice and nonhuman primates
- (2013) K. S. Cooke et al. BLOOD
- The effects of the anti-hepcidin Spiegelmer NOX-H94 on inflammation-induced anemia in cynomolgus monkeys
- (2013) F. Schwoebel et al. BLOOD
- Iron refractory iron deficiency anemia
- (2013) L. De Falco et al. HAEMATOLOGICA
- A Highly Potent and Specific MET Therapeutic Protein Antagonist with Both Ligand-Dependent and Ligand-Independent Activity
- (2013) Shane A. Olwill et al. MOLECULAR CANCER THERAPEUTICS
- Improved Mass Spectrometry Assay For Plasma Hepcidin: Detection and Characterization of a Novel Hepcidin Isoform
- (2013) Coby M. M. Laarakkers et al. PLoS One
- First-in-Human Phase I Study of PRS-050 (Angiocal), an Anticalin Targeting and Antagonizing VEGF-A, in Patients with Advanced Solid Tumors
- (2013) Klaus Mross et al. PLoS One
- Molecular Mechanism of Hepcidin-Mediated Ferroportin Internalization Requires Ferroportin Lysines, Not Tyrosines or JAK-STAT
- (2012) Sandra L. Ross et al. Cell Metabolism
- Pharmacokinetics of Anti-hepcidin Monoclonal Antibody Ab 12B9m and Hepcidin in Cynomolgus Monkeys
- (2010) Jim J. Xiao et al. AAPS Journal
- Hepcidin and Disorders of Iron Metabolism
- (2010) Tomas Ganz et al. Annual Review of Medicine
- Antihepcidin antibody treatment modulates iron metabolism and is effective in a mouse model of inflammation-induced anemia
- (2010) B. J. Sasu et al. BLOOD
- Animal research: Reporting in vivo experiments: The ARRIVE guidelines
- (2010) Carol Kilkenny et al. BRITISH JOURNAL OF PHARMACOLOGY
- Immunochemical and Mass-Spectrometry-Based Serum Hepcidin Assays for Iron Metabolism Disorders
- (2010) J. J. C. Kroot et al. CLINICAL CHEMISTRY
- Interspecies Scaling of Receptor-Mediated Pharmacokinetics and Pharmacodynamics of Type I Interferons
- (2010) Leonid Kagan et al. PHARMACEUTICAL RESEARCH
- High-Affinity Recognition of Lanthanide(III) Chelate Complexes by a Reprogrammed Human Lipocalin 2
- (2009) Hyun Jin Kim et al. JOURNAL OF THE AMERICAN CHEMICAL SOCIETY
- An engineered lipocalin specific for CTLA-4 reveals a combining site with structural and conformational features similar to antibodies
- (2009) D. Schonfeld et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Iron Sequestration and Anemia of Inflammation
- (2009) Tomas Ganz et al. SEMINARS IN HEMATOLOGY
Add your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload NowCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now